Art

J-GLOBAL ID：201702248840715061   Reference number：17A0135920

Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor

チャールソン併存疾患指数はチロシンキナーゼ阻害剤で治療したCML患者の転帰不良を予測する

Author (10)： Uemura Makiko (Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-town, Japan) ,  Imataki Osamu (Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-town, Japan) ,  Imataki Osamu (Division of Hematology and Stem Cell Transplantation, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-town, Kagawa, Japan) ,  Kawachi Yasunori (Division of Hematology, Department of Internal Medicine, Kaisei General Hospital, The Taijukai Foundation, Sakaide City, Kagawa, Japan) ,  Kawachi Yasunori (Division of Hematology, Department of Internal Medicine, Takamatsu Red Cross Hospital, Takamatsu City, Kagawa, Japan) ,  Kawakami Kimihiro (Division of Hematology, Department of Internal Medicine, Kagawa Prefectural Central Hospital, Takamatsu City, Kagawa, Japan) ,  Hoshijima Yasuo (Department of Internal Medicine, Takamatsu Municipal Hospital, Takamatsu City, Kagawa, Japan) ,  Matsuoka Akihito (Department of Internal Medicine, Sakaide City Hospital, Sakaide City, Kagawa, Japan) ,  Matsuoka Akihito (Division of Hematology, Department of Internal Medicine, Mitoyo General Hospital, Kanonji City, Kagawa, Japan) ,  Kadowaki Norimitsu (Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-town, Japan)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 104  Issue： 5  Page： 621-627  Publication year： Nov. 2016 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： *criterion ,...
Semi thesaurus term： *チャールソン併存疾患指数 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0135920&from=J-GLOBAL&jstjournalNo=F0888A") }}

Author keywords (5)： Chronic myeloid leukemia ,  Tyrosine kinase inhibitor ,  Charlson comorbidity index ,  Sokal score ,  Hasford score

JST classification (2)： Clinical oncology in general  (GE03010Y) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Reference (18)：

• Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120:1390-7.
• Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17.
• Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284-92.
• Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553-61.
• Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789-99.

Terms in the title (6)： チャールソン併存疾患指数 ,  チロシンキナーゼ阻害剤 ,  治療 ,  CML ,  患者の転帰 ,  予測